Pharmaniaga Q1 net profit slips to RM2.65mil

Pharmaniaga says Indonesia remains a key growth driver.

PETALING JAYA: Pharmaniaga Bhd remains steadfast in its commitment to meeting its obligations to the Health Ministry and will continue to negotiate on the logistics and distribution concession agreement, which is expected to be concluded by the end of the interim period on June 30, 2023.

“Our biopharmaceutical facilities are set to produce commercial batches of halal vaccines and insulin by 2025 and these facilities will further solidify Pharmaniaga’s global standing as a reputable vaccine and insulin manufacturer, creating fresh sales prospects both locally and internationally,” it said in a filing with Bursa Malaysia yesterday.